View Financial HealthAlgorae Pharmaceuticals 배당 및 자사주 매입배당 기준 점검 0/6Algorae Pharmaceuticals 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-0.02%자사주 매입 수익률총 주주 수익률-0.02%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Apr 02Algorae Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 1.0722 million.Algorae Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 1.0722 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 89,350,001 Price\Range: AUD 0.012 Transaction Features: Subsequent Direct Listing공시 • Aug 14Algorae Pharmaceuticals Limited, Annual General Meeting, Oct 02, 2025Algorae Pharmaceuticals Limited, Annual General Meeting, Oct 02, 2025.공시 • Apr 03Algorae Pharmaceuticals Limited Announces the Appointment of Vishal Shah as Chief Commercial OfficerAlgorae Pharmaceuticals Limited announced the appointment of seasoned pharmaceutical executive Vishal Shah as Chief Commercial Officer (`CCO'). With a distinguished career spanning over 20 years in pharmaceuticals, biotechnology, and healthcare, Mr. Shah will spearhead Algorae's commercial strategy to accelerate growth and expansion into complimentary pharmaceutical market segments. Mr. Shah joins Algorae from HPS Pharmacies, where he was responsible for shaping procurement strategy, driving revenue growth, and expanding market reach. At HPS Pharmacies, he was instrumental in accelerating business expansion, strengthening the Company's market position, and forging high-value partnerships. Prior to EBOS, Mr. Shah held senior leadership roles at Baxter Healthcare, including Associate Director of Pharmaceuticals for Asia-Pacific (`APAC') and Head of Pharmaceuticals Australia/New Zealand (`ANZ'). At Baxter, a global leader in medical technology and pharmaceuticals with a market capitalisation exceeding AUD 27 billion, he successfully led commercial strategy, executed major product launches, and oversaw growth initiatives that enhanced both revenue and earnings. His expertise spans navigating regulatory landscapes, establishing strategic alliances, and optimising commercial operations across international markets. Mr. Shah has a Pharmacy Degree, a Master's in Applied Science (Biotechnology), and an MBA from Western Sydney University, providing him with of the necessary scientific expertise and commercial acumen for his new role with Algorae.공시 • Sep 06Algorae Pharmaceuticals Limited, Annual General Meeting, Oct 25, 2024Algorae Pharmaceuticals Limited, Annual General Meeting, Oct 25, 2024.공시 • Jul 01Algorae Pharmaceuticals Limited Announces Change of Company SecretaryAlgorae Pharmaceuticals Limited announced the appointment of Ms Jennifer Voon as Company Secretary, effective 1 July 2024. Ms Voon is a Chartered Accountant with over a decade's experience in financial services, with a focus on capital markets and compliance. Ms Maria Clemente of Automic Group will step down as Company Secretary effectively immediately.공시 • Jan 17Algorae Pharmaceuticals Limited Announces Change of Company SecretaryAlgorae Pharmaceuticals Limited advised that Mr. Madhukar Bhalla has resigned as Company Secretary of the Company, effective 17 January 2024. Mr. Bhalla has tendered his resignation from the Company and will be replaced by Ms Leah Pieris of Automic Group as Company Secretary, with effect from 17 January 2024. Ms Pieris is a Chartered Company Secretary and a Fellow of the Governance Institute of Australia. Ms Pieris is a member of Automic Group, which provides market leading, cloud based share registry technology, compliance and governance solutions, supported by a tailored range of professional services. As a member of Automic Group’s Company Secretary team, Ms Pieris assists ASX listed companies across a range of industries.공시 • Sep 12Algorae Pharmaceuticals Limited, Annual General Meeting, Nov 02, 2023Algorae Pharmaceuticals Limited, Annual General Meeting, Nov 02, 2023, at 12:00 E. Australia Standard Time.공시 • Jul 29Living Cell Technologies Limited, Annual General Meeting, Sep 01, 2023Living Cell Technologies Limited, Annual General Meeting, Sep 01, 2023, at 12:00 E. Australia Standard Time. Location: Thomson Geer Level 23, Rialto South Tower, 525 Collins Street, Melbourne Australia Agenda: To consider change of company name; to ratification of the issue of shares and options under the pre-Entitlement offer placement; to consider Ratification of the issue of Shares and Options under the Greenshoe Placement; to consider Ratification of the issue of Lead Manager Options; to consider and Approve of the issue of Lead Manager Options; to consider and Approve of the issue of Performance Shares to David Hainsworth; and to consider and Approve of the issue of Performance Shares to Brad Dilkes.공시 • Jul 04Living Cell Technologies Limited Announces Management ChangesLiving Cell Technologies Limited (LCT) announced that it has made the following changes to its board of directors: the appointment of Mr. Bradley Latham as a non-executive director of LCT, effective immediately, the appointment of Professor Carolyn Sue to the position of Chief Medical Officer (CMO) of NTCELL and simultaneous resignation from her non-executive director position, effective 1 July 2023. Mr. Latham is an accomplished and energetic businessperson with strong commercial acumen and extensive business experience. The majority of Mr. Latham's working career has been with Sydney Markets where he has worked his way through the ranks until appointed CEO of the group in 2006. Mr. Latham is experienced in all matters of business, including strategic planning, financial management, business development, operational management, and marketing of various successful brands, which has been instrumental in maintaining Sydney Markets' position as one of the premier privately owned markets in the world. Mr. Latham has a proven track record of business leadership and has a strong understanding of good corporate governance and risk management. He possesses an ability to identify and assess strategic growth opportunities, which is advantageous for LCT as it assesses various potential opportunities to expand and diversify its drug candidate profile. Mr. Latham holds a Master of Management from the University of New South Wales. Professor Carolyn Sue, MBBS, PhD, FRACP, is an internationally recognised clinician-scientist, a leader in Parkinson's disease and a medicine alum of UNSW who trained at Westmead Hospital and at Columbia University in the United States. Carolyn's experience, expertise and contributions to Parkinson's disease research have been widely recognised. She holds leadership roles in the Movement Disorder Society of Australia and New Zealand, and International Parkinson's disease and Movement Disorder Society, and is a Fellow of the Australian Academy of Medical Sciences. In 2019, Carolyn was awarded a member of the Order of Australia (AM) in recognition of her significant services to medicine. Professor Sue is leading a scientific review of the NTCELL clinical trial protocol and development plan in conjunction with a multi-disciplinary panel of scientific experts advising on various aspects of the NTCELL project. Professor Sue has resigned from her non-executive director position to focus all necessary attention on the role of CMO of NTCELL.공시 • Jun 09Living Cell Technologies Limited Appoints James A Mckenna as Chief Scientific OfficerLiving Cell Technologies Limited announced the appointment of Dr. James A Mckenna as Chief Scientific Officer (`CSO') of the Company. Dr. Mckenna is an experienced research scientist who holds a PhD in biochemistry and molecular biology from the University of Melbourne. Dr. Mckenna has been a full-time research scientist for 23 years, with experience in academic science, commercial drug development and intellectual property generation. Most recently, he held a leadership position at an ASX listed biotechnology company where he managed and was involved in teams to advance pre-clinical and clinical research and development (R&D) programs for the purpose of achieving US Food and Drug Administration (FDA) registration. Dr. Mckenna's appointment coincides with LCT's corporate strategy to expand and diversify the Company's development pipeline. The role of CSO will include: research pertaining to drug candidate development, arrangement of pre-clinical and clinical studies, and liaison with intellectual property attorneys and pharmaceutical regulators. Dr. Mckenna commences the role of CSO on 19 June 2023.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 LVCL.F 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: LVCL.F 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Algorae Pharmaceuticals 배당 수익률 vs 시장LVCL.F의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (LVCL.F)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.2%업계 평균 (Biotechs)2.4%분석가 예측 (LVCL.F) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 LVCL.F 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 LVCL.F 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 LVCL.F 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: LVCL.F 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/03/21 01:51종가2025/12/22 00:00수익2025/12/31연간 수익2025/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Algorae Pharmaceuticals Limited는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Apr 02Algorae Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 1.0722 million.Algorae Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 1.0722 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 89,350,001 Price\Range: AUD 0.012 Transaction Features: Subsequent Direct Listing
공시 • Aug 14Algorae Pharmaceuticals Limited, Annual General Meeting, Oct 02, 2025Algorae Pharmaceuticals Limited, Annual General Meeting, Oct 02, 2025.
공시 • Apr 03Algorae Pharmaceuticals Limited Announces the Appointment of Vishal Shah as Chief Commercial OfficerAlgorae Pharmaceuticals Limited announced the appointment of seasoned pharmaceutical executive Vishal Shah as Chief Commercial Officer (`CCO'). With a distinguished career spanning over 20 years in pharmaceuticals, biotechnology, and healthcare, Mr. Shah will spearhead Algorae's commercial strategy to accelerate growth and expansion into complimentary pharmaceutical market segments. Mr. Shah joins Algorae from HPS Pharmacies, where he was responsible for shaping procurement strategy, driving revenue growth, and expanding market reach. At HPS Pharmacies, he was instrumental in accelerating business expansion, strengthening the Company's market position, and forging high-value partnerships. Prior to EBOS, Mr. Shah held senior leadership roles at Baxter Healthcare, including Associate Director of Pharmaceuticals for Asia-Pacific (`APAC') and Head of Pharmaceuticals Australia/New Zealand (`ANZ'). At Baxter, a global leader in medical technology and pharmaceuticals with a market capitalisation exceeding AUD 27 billion, he successfully led commercial strategy, executed major product launches, and oversaw growth initiatives that enhanced both revenue and earnings. His expertise spans navigating regulatory landscapes, establishing strategic alliances, and optimising commercial operations across international markets. Mr. Shah has a Pharmacy Degree, a Master's in Applied Science (Biotechnology), and an MBA from Western Sydney University, providing him with of the necessary scientific expertise and commercial acumen for his new role with Algorae.
공시 • Sep 06Algorae Pharmaceuticals Limited, Annual General Meeting, Oct 25, 2024Algorae Pharmaceuticals Limited, Annual General Meeting, Oct 25, 2024.
공시 • Jul 01Algorae Pharmaceuticals Limited Announces Change of Company SecretaryAlgorae Pharmaceuticals Limited announced the appointment of Ms Jennifer Voon as Company Secretary, effective 1 July 2024. Ms Voon is a Chartered Accountant with over a decade's experience in financial services, with a focus on capital markets and compliance. Ms Maria Clemente of Automic Group will step down as Company Secretary effectively immediately.
공시 • Jan 17Algorae Pharmaceuticals Limited Announces Change of Company SecretaryAlgorae Pharmaceuticals Limited advised that Mr. Madhukar Bhalla has resigned as Company Secretary of the Company, effective 17 January 2024. Mr. Bhalla has tendered his resignation from the Company and will be replaced by Ms Leah Pieris of Automic Group as Company Secretary, with effect from 17 January 2024. Ms Pieris is a Chartered Company Secretary and a Fellow of the Governance Institute of Australia. Ms Pieris is a member of Automic Group, which provides market leading, cloud based share registry technology, compliance and governance solutions, supported by a tailored range of professional services. As a member of Automic Group’s Company Secretary team, Ms Pieris assists ASX listed companies across a range of industries.
공시 • Sep 12Algorae Pharmaceuticals Limited, Annual General Meeting, Nov 02, 2023Algorae Pharmaceuticals Limited, Annual General Meeting, Nov 02, 2023, at 12:00 E. Australia Standard Time.
공시 • Jul 29Living Cell Technologies Limited, Annual General Meeting, Sep 01, 2023Living Cell Technologies Limited, Annual General Meeting, Sep 01, 2023, at 12:00 E. Australia Standard Time. Location: Thomson Geer Level 23, Rialto South Tower, 525 Collins Street, Melbourne Australia Agenda: To consider change of company name; to ratification of the issue of shares and options under the pre-Entitlement offer placement; to consider Ratification of the issue of Shares and Options under the Greenshoe Placement; to consider Ratification of the issue of Lead Manager Options; to consider and Approve of the issue of Lead Manager Options; to consider and Approve of the issue of Performance Shares to David Hainsworth; and to consider and Approve of the issue of Performance Shares to Brad Dilkes.
공시 • Jul 04Living Cell Technologies Limited Announces Management ChangesLiving Cell Technologies Limited (LCT) announced that it has made the following changes to its board of directors: the appointment of Mr. Bradley Latham as a non-executive director of LCT, effective immediately, the appointment of Professor Carolyn Sue to the position of Chief Medical Officer (CMO) of NTCELL and simultaneous resignation from her non-executive director position, effective 1 July 2023. Mr. Latham is an accomplished and energetic businessperson with strong commercial acumen and extensive business experience. The majority of Mr. Latham's working career has been with Sydney Markets where he has worked his way through the ranks until appointed CEO of the group in 2006. Mr. Latham is experienced in all matters of business, including strategic planning, financial management, business development, operational management, and marketing of various successful brands, which has been instrumental in maintaining Sydney Markets' position as one of the premier privately owned markets in the world. Mr. Latham has a proven track record of business leadership and has a strong understanding of good corporate governance and risk management. He possesses an ability to identify and assess strategic growth opportunities, which is advantageous for LCT as it assesses various potential opportunities to expand and diversify its drug candidate profile. Mr. Latham holds a Master of Management from the University of New South Wales. Professor Carolyn Sue, MBBS, PhD, FRACP, is an internationally recognised clinician-scientist, a leader in Parkinson's disease and a medicine alum of UNSW who trained at Westmead Hospital and at Columbia University in the United States. Carolyn's experience, expertise and contributions to Parkinson's disease research have been widely recognised. She holds leadership roles in the Movement Disorder Society of Australia and New Zealand, and International Parkinson's disease and Movement Disorder Society, and is a Fellow of the Australian Academy of Medical Sciences. In 2019, Carolyn was awarded a member of the Order of Australia (AM) in recognition of her significant services to medicine. Professor Sue is leading a scientific review of the NTCELL clinical trial protocol and development plan in conjunction with a multi-disciplinary panel of scientific experts advising on various aspects of the NTCELL project. Professor Sue has resigned from her non-executive director position to focus all necessary attention on the role of CMO of NTCELL.
공시 • Jun 09Living Cell Technologies Limited Appoints James A Mckenna as Chief Scientific OfficerLiving Cell Technologies Limited announced the appointment of Dr. James A Mckenna as Chief Scientific Officer (`CSO') of the Company. Dr. Mckenna is an experienced research scientist who holds a PhD in biochemistry and molecular biology from the University of Melbourne. Dr. Mckenna has been a full-time research scientist for 23 years, with experience in academic science, commercial drug development and intellectual property generation. Most recently, he held a leadership position at an ASX listed biotechnology company where he managed and was involved in teams to advance pre-clinical and clinical research and development (R&D) programs for the purpose of achieving US Food and Drug Administration (FDA) registration. Dr. Mckenna's appointment coincides with LCT's corporate strategy to expand and diversify the Company's development pipeline. The role of CSO will include: research pertaining to drug candidate development, arrangement of pre-clinical and clinical studies, and liaison with intellectual property attorneys and pharmaceutical regulators. Dr. Mckenna commences the role of CSO on 19 June 2023.